Govt Job: for M.Pharm, M.Sc as Junior Research Fellow

The Birla Institute of Technology and Science, BITS Pilani is an all-India Institute for higher education. The primary motive of BITS is to train young men and women able and eager to create and put into action such ideas, methods, techniques and information.

The Institute is a dream come true of its founder late Mr G.D.Birla – an eminent industrialist, a participant in Indian freedom struggle and a close associate of the Father of Indian Nation late Mr. Mohandas Karamchand Gandhi.

Post : Junior Research Fellow

Applications are invited from suitable candidates for the post of Junior Research Fellow to work on a research project sponsored by DST-SERB. under the supervision of Dr. Sajeli Begum, Department of Pharmacy, BITS-Pilani, Hyderabad campus.

Title of the project : Synthesis of novel coumarin-based lignans targeting pro-inflammatory cytokines for the treatment of chronic kidney diseases

Duration of the project : 3 years

Fellowship amount : Rs. 31,000/- month

Eligibility requirements :
1. M.Pharm (Medicinal Chemistry)’ M.Sc.(Organic Chemistry) with hands-on experience in synthesis and purification techniques

2. Candidates with minimum of two-years pharmaceutical industry experience will be given preference.

3. Experience in cell culture studies and animal handling would be an added advantage.

4. In addition, good oral and written communications skills are highly desirable

Interested candidates with the above mentioned qualifications can send the application along with their CV giving detailed information about their educational qualifications, research / work experience and published research papers, if any, by 13-11-2021. to the Principal Investigator, Dr. Sajeli Begum via email : sajeli@hyderabad.bits-pilani.ac.in.

Please note that only qualified and suitable candidates will be called for the interview to be held at BITS-Pilani, Hyderabad Campus in the third week of Not/. 2021 through online mode. A selected candidate may be permitted to register for the Ph.D Programme of BITS. Pilani, subject to the fulfillment of the requirements.

Related Posts

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise